Compare NetApp Inc. (NTAP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? NetApp Inc. trades at $201.98 (market cap $38.95B), while State Street SPDR S&P Biotech ETF trades at $159.08. The key difference: NetApp Inc. pays a 1.05% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| NTAP | XBI | |
|---|---|---|
Market Cap | $38.95B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $198.72 | $164.28 |
52-Week Low | $94.11 | $86.92 |
Enterprise Value | $38.10B | — |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $200.96, up 1.13% with strong technical momentum as it approaches resistance near $201. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.43 vs. $2.27 expected) and impressive profitability metrics including 70.74% gross margin and 106.73% ROE. Recent acquisitions of JetStream Software and DataPelago strengthen the company's AI infrastructure capabilities, positioning it for growth in the enterprise data storage market.
Outlook remains positive with Wall Street analysts maintaining a mixed but leaning bullish stance (36.62% Buy ratings). Key opportunities include AI-driven demand for data infrastructure, while risks involve elevated valuation multiples (P/E 31.26) and competitive pressures in the storage sector. The current price sits near analyst consensus target of $170.73, suggesting limited near-term upside potential.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
